search
Back to results

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Primary Purpose

Refractory Epilepsy

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
diazepam nasal spray
diazepam rectal gel
Sponsored by
Acorda Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractory Epilepsy focused on measuring Seizures, Epilepsy

Eligibility Criteria

12 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of refractory epilepsy
  • Body weight 26 to 111 kilogram (kg) inclusive
  • Other inclusion criteria apply

Exclusion Criteria:

  • Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product
  • Female subject who is pregnant, breastfeeding, or planning to become pregnant
  • Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam
  • Other exclusion criteria apply

Sites / Locations

  • Acorda Site #115
  • Acorda Site #127
  • Acorda Site #101
  • Acorda Site #125
  • Acorda Site #104
  • Acorda Site #111
  • Acorda Site #102
  • Acorda Site #110
  • Acorda Site #117
  • Acorda Site #112
  • Acorda Site #128
  • Acorda Site #121
  • Acorda Site #123
  • Acorda Site #119
  • Acorda Site #132
  • Acorda Site #114
  • Acorda Site #116
  • Acorda Site #105
  • Acorda Site #130
  • Acorda Site #103
  • Acorda Site #122
  • Acorda Site #108

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

diazepam nasal spray (DZNS)

diazepam rectal gel (DRG)

Arm Description

One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.

Outcomes

Primary Outcome Measures

AUC 0-24h
Relative bioavailability based on area under time plasma concentration curve.
Cmax
Relative bioavailability based on maximum observed plasma concentration.

Secondary Outcome Measures

Focused Nasal Exam (Part A)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Focused Nasal Exam (Part B)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Smell Identification Test (SIT)
The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
Taste Change Questionnaire
Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.

Full Information

First Posted
June 15, 2015
Last Updated
September 20, 2018
Sponsor
Acorda Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT02474407
Brief Title
Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
Official Title
An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Terminated
Study Start Date
June 2015 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Acorda Therapeutics

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)
Detailed Description
To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractory Epilepsy
Keywords
Seizures, Epilepsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
diazepam nasal spray (DZNS)
Arm Type
Experimental
Arm Description
One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Arm Title
diazepam rectal gel (DRG)
Arm Type
Active Comparator
Arm Description
A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
Intervention Type
Drug
Intervention Name(s)
diazepam nasal spray
Other Intervention Name(s)
Diazepam
Intervention Type
Drug
Intervention Name(s)
diazepam rectal gel
Other Intervention Name(s)
Diastat®, AcuDial™
Primary Outcome Measure Information:
Title
AUC 0-24h
Description
Relative bioavailability based on area under time plasma concentration curve.
Time Frame
24 hours
Title
Cmax
Description
Relative bioavailability based on maximum observed plasma concentration.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Focused Nasal Exam (Part A)
Description
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time Frame
pre-dose (day 1) up to 24 hours post-dose
Title
Focused Nasal Exam (Part B)
Description
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time Frame
pre-dose (day 1) up to 24 hours post-dose
Title
Smell Identification Test (SIT)
Description
The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
Time Frame
day 1 up to day 31
Title
Taste Change Questionnaire
Description
Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.
Time Frame
Up to 24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of refractory epilepsy Body weight 26 to 111 kilogram (kg) inclusive Other inclusion criteria apply Exclusion Criteria: Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product Female subject who is pregnant, breastfeeding, or planning to become pregnant Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam Other exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lee Min Jae
Organizational Affiliation
SK Biopharmaceuticals Co, Ltd
Official's Role
Study Director
Facility Information:
Facility Name
Acorda Site #115
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Acorda Site #127
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Acorda Site #101
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Acorda Site #125
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96817
Country
United States
Facility Name
Acorda Site #104
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40513
Country
United States
Facility Name
Acorda Site #111
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Acorda Site #102
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Facility Name
Acorda Site #110
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48105
Country
United States
Facility Name
Acorda Site #117
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Facility Name
Acorda Site #112
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63131
Country
United States
Facility Name
Acorda Site #128
City
Edison
State/Province
New Jersey
ZIP/Postal Code
08818
Country
United States
Facility Name
Acorda Site #121
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
Acorda Site #123
City
Amherst
State/Province
New York
ZIP/Postal Code
14226
Country
United States
Facility Name
Acorda Site #119
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Acorda Site #132
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Acorda Site #114
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Acorda Site #116
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Acorda Site #105
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Acorda Site #130
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
Acorda Site #103
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Acorda Site #122
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Acorda Site #108
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

We'll reach out to this number within 24 hrs